ReviewInternational journal of molecular sciences2022
Chronic Kidney Disease and Gut Microbiota: What Is Their Connection in Early Life?
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 47 citations in OpenAlex.
- The gut-kidney axis in pediatric acute kidney injury: a review of pathophysiological mechanisms and therapeutic frontiers.Pediatric nephrology (Berlin, Germany) · 2026Review
- Paishi granule inhibits calcium oxalate-induced oxidative stress kidney injury after gut microbiota transformation: a multi-omics analysis combined in vivo and in vitro study.Chinese medicine · 2026Article
- Life-Course Programming of Kidney Disease: Roles of Gut Microbiota Dysbiosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
- Mechanisms Linking Recurrent Bacterial Urinary Tract Infections to Chronic Kidney Disease Progression.International journal of molecular sciences · 2026Review
- The gut-kidney axis in chronic kidney disease: a vicious cycle of microbial dysbiosis and uremic toxin accumulation.Frontiers in immunology · 2026Review
- Early-Life Hydrogen Sulfide Signaling as a Target for Cardiovascular-Kidney-Metabolic Syndrome Reprogramming.Antioxidants (Basel, Switzerland) · 2025Review
- Oxidative Stress in Maternal and Offspring Kidney Disease and Hypertension: A Life-Course Perspective.Antioxidants (Basel, Switzerland) · 2025Review
- Pneumoconiosis and Chronic Diseases: A Narrative Review.Iranian journal of public health · 2025Review
- Perturbed gut microbiota and serum metabolites are associated with progressive renal fibrosis.Frontiers in medicine · 2025Article
- Advances in kidney disease: pathogenesis and therapeutic targets.Frontiers in medicine · 2025Review
- Kidney Programming and Hypertension: Linking Prenatal Development to Adulthood.International journal of molecular sciences · 2024Review
- Preterm Birth and Kidney Health: From the Womb to the Rest of Life.Children (Basel, Switzerland) · 2024Review
- Review
- Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease.Clinical kidney journal · 2024Review
- Prediction and causal inference of hyperuricemia using gut microbiota.Scientific reports · 2024Article
- Exposure Patterns of Multiple Pesticides and Urinary Alterations of Trimethylamine (TMA) and Trimethylamine N-Oxide (TMAO) among Pregnant Women.Environment & health (Washington, D.C.) · 2024Article
- Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?Advances in therapy · 2024Article
- The Kidney-Gut Axis as a Novel Target for Nutritional Intervention to Counteract Chronic Kidney Disease Progression.Metabolites · 2024Review
- Hesperidin alleviates zinc-induced nephrotoxicity via the gut-kidney axis in swine.Frontiers in cellular and infection microbiology · 2024Article
- Preventive effect ofFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The gut-kidney interaction implicating chronic kidney disease (CKD) has been the focus of increasing interest in recent years. Gut microbiota-targeted therapies could prevent CKD and its comorbidities. Considering that CKD can originate in early life, its treatment and prevention should start in childhood or even earlier in fetal life. Therefore, a better understanding of how the early-life gut microbiome impacts CKD in later life and how to develop ideal early interventions are unmet needs to reduce CKD. The purpose of the current review is to summarize (1) the current evidence on the gut microbiota dysbiosis implicated in pediatric CKD; (2) current knowledge supporting the impact of the gut-kidney axis in CKD, including inflammation, immune response, alterations of microbiota compositions, short-chain fatty acids, and uremic toxins; and (3) an overview of the studies documenting early gut microbiota-targeted interventions in animal models of CKD of developmental origins. Treatment options include prebiotics, probiotics, postbiotics, etc. To accelerate the transition of gut microbiota-based therapies for early prevention of CKD, an extended comprehension of gut microbiota dysbiosis implicated in renal programming is needed, as well as a greater focus on pediatric CKD for further clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.